A carregar...
Anti–CTLA-4 immunotherapy does not deplete FOXP3(+) regulatory T cells (Tregs) in human cancers
PURPOSE: CTLA-4 was the first inhibitory immune checkpoint to be identified. Two monoclonal antibodies, ipilimumab (IgG1) and tremelimumab (IgG2), which block the function of CTLA-4, have demonstrated durable clinical activity in a subset of patients with advanced solid malignancies by augmenting ef...
Na minha lista:
| Publicado no: | Clin Cancer Res |
|---|---|
| Main Authors: | , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6348141/ https://ncbi.nlm.nih.gov/pubmed/30054281 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-18-0762 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|